What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab duringCOVID-19 or asymptomatic infections due toSARS-CoV-2?

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCRIADO, Paulo Ricardo
dc.contributor.authorPAGLIARI, Carla
dc.contributor.authorCRIADO, Roberta Fachini Jardim
dc.contributor.authorMARQUES, Gabriela Franco
dc.contributor.authorJR, Walter Belda
dc.date.accessioned2021-02-18T13:28:32Z
dc.date.available2021-02-18T13:28:32Z
dc.date.issued2020
dc.description.abstractCoronavirus disease (COVID-19) pandemic presents several dermatological manifestations described in the present indexed literature, with around 700 cases reported until May 2020, some described as urticaria or urticarial rashes. Urticaria is constituted by evanescent erythematous-edematous lesions (wheals and flare), which does not persist in the same site for more than 24 to 48 hours and appears in other topographic localization, resolving without residual hyper pigmentation. During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, some cytokines are synthesized, including Interferon (IFN) type I, TNF-alpha, and chemokines which may induce mast cells (MCs) and basophils degranulation by mechanisms similar to the autoinflammatory monogenic or polygenic diseases. In this article, we discuss the spectrum of the urticaria and urticarial-like lesions in the COVID-19's era, besides other aspects related to innate and adaptative immune response to viral infections, interactions between dermal dendritic cells and MCs, and degranulation of MCs by different stimuli. Plasmacytoid dendritic cells share, in allergic patients, expression of the high-affinity IgE receptors on cell membranes and demonstrated a low pattern of type I IFN secretion in viral infections. We discuss the previous descriptions of the effects of omalizumab, a monoclonal antibody directed to IgE and high-affinity IgE receptors, to improve the IFN responses and enhance their antiviral effects.eng
dc.description.indexMEDLINEeng
dc.identifier.citationDERMATOLOGIC THERAPY, v.33, n.6, article ID e14068, 9p, 2020
dc.identifier.doi10.1111/dth.14068
dc.identifier.eissn1529-8019
dc.identifier.issn1396-0296
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/39159
dc.language.isoeng
dc.publisherWILEYeng
dc.relation.ispartofDermatologic Therapy
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright WILEYeng
dc.subjectCOVID-19eng
dc.subjectdendritic cellseng
dc.subjectinnate immunityeng
dc.subjectmast cellseng
dc.subjectSARS-CoV-2eng
dc.subjecturticariaeng
dc.subject.otherdengue virus-infectioneng
dc.subject.otherimmune-responseseng
dc.subject.otherigeeng
dc.subject.otherasthmaeng
dc.subject.otherrhinoviruseng
dc.subject.othercovid-19eng
dc.subject.otherreceptoreng
dc.subject.otherbasophilseng
dc.subject.othercytokineseng
dc.subject.othersarseng
dc.subject.wosDermatologyeng
dc.titleWhat the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab duringCOVID-19 or asymptomatic infections due toSARS-CoV-2?eng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalCRIADO, Roberta Fachini Jardim:Ctr Univ Saude ABC, Dermatol Dept, Santo Andre, SP, Brazil
hcfmusp.citation.scopus24
hcfmusp.contributor.author-fmusphcPAULO RICARDO CRIADO
hcfmusp.contributor.author-fmusphcCARLA PAGLIARI
hcfmusp.contributor.author-fmusphcGABRIELA FRANCO MARQUES
hcfmusp.contributor.author-fmusphcWALTER BELDA JUNIOR
hcfmusp.description.articlenumbere14068
hcfmusp.description.issue6
hcfmusp.description.volume33
hcfmusp.origemWOS
hcfmusp.origem.pubmed32713127
hcfmusp.origem.scopus2-s2.0-85089364916
hcfmusp.origem.wosWOS:000558910000001
hcfmusp.publisher.cityHOBOKENeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAghdam MK, 2020, INFECT DIS-NOR, V52, P427, DOI 10.1080/23744235.2020.1747634eng
hcfmusp.relation.referenceAtta AM, 2010, INT ARCH ALLERGY IMM, V152, P401, DOI 10.1159/000288293eng
hcfmusp.relation.referenceBusse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705eng
hcfmusp.relation.referenceButtignol M, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0630-xeng
hcfmusp.relation.referenceCardet JC, 2019, J ALLERGY CLIN IMMUN, V143, P923, DOI 10.1016/j.jaci.2019.01.016eng
hcfmusp.relation.referenceCharles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159eng
hcfmusp.relation.referenceChen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681eng
hcfmusp.relation.referenceCheng YD, 2019, J INFECT PUBLIC HEAL, V12, P878, DOI 10.1016/j.jiph.2019.05.017eng
hcfmusp.relation.referenceContoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462eng
hcfmusp.relation.referenceCrowl JT, 2017, ANNU REV IMMUNOL, V35, P313, DOI 10.1146/annurev-immunol-051116-052331eng
hcfmusp.relation.referenceDema B, 2014, J EXP MED, V211, P2159, DOI 10.1084/jem.20140066eng
hcfmusp.relation.referenceDema B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090424eng
hcfmusp.relation.referenceDong X, 2020, ALLERGY, V75, P1699, DOI 10.1111/all.14289eng
hcfmusp.relation.referenceDudeck A, 2019, J ALLERGY CLIN IMMUN, V144, pS4, DOI 10.1016/j.jaci.2018.10.054eng
hcfmusp.relation.referenceDurrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023eng
hcfmusp.relation.referenceEsquivel A, 2017, AM J RESP CRIT CARE, V196, P985, DOI 10.1164/rccm.201701-0120OCeng
hcfmusp.relation.referenceFerro F, 2020, CLIN EXP RHEUMATOL, V38, P175eng
hcfmusp.relation.referenceFukuda M, 2013, J INNATE IMMUN, V5, P163, DOI 10.1159/000343895eng
hcfmusp.relation.referenceGill MA, 2018, J ALLERGY CLIN IMMUN, V141, P1735, DOI 10.1016/j.jaci.2017.07.035eng
hcfmusp.relation.referenceGill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194eng
hcfmusp.relation.referenceGraham AC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00238eng
hcfmusp.relation.referenceHamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570eng
hcfmusp.relation.referenceHasni S, 2019, ARTHRITIS RHEUMATOL, V71, P1135, DOI 10.1002/art.40828eng
hcfmusp.relation.referenceHenault J, 2016, NAT IMMUNOL, V17, P196, DOI 10.1038/ni.3326eng
hcfmusp.relation.referenceIgawa S, 2017, TRANSL RES, V184, P68, DOI 10.1016/j.trsl.2017.03.003eng
hcfmusp.relation.referenceJegalian AG, 2009, ADV ANAT PATHOL, V16, P392, DOI 10.1097/PAP.0b013e3181bb6bc2eng
hcfmusp.relation.referenceKantor DB, 2016, J ALLERGY CLIN IMMUN, V138, P1467, DOI 10.1016/j.jaci.2016.04.044eng
hcfmusp.relation.referenceKing CA, 2000, J VIROL, V74, P7146, DOI 10.1128/JVI.74.15.7146-7150.2000eng
hcfmusp.relation.referenceKritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritaseng
hcfmusp.relation.referenceLambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049eng
hcfmusp.relation.referenceLi G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685eng
hcfmusp.relation.referenceMantri CK, 2019, J CLIN INVEST, V129, P1094, DOI 10.1172/JCI122530eng
hcfmusp.relation.referenceMarone G, 2016, INT ARCH ALLERGY IMM, V171, P158, DOI 10.1159/000452889eng
hcfmusp.relation.referenceMarshall JS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174241eng
hcfmusp.relation.referenceMauad T, 2010, AM J RESP CRIT CARE, V181, P72, DOI 10.1164/rccm.200909-1420OCeng
hcfmusp.relation.referencePagano JS, 2004, SEMIN CANCER BIOL, V14, P453, DOI 10.1016/j.semcancer.2004.06.009eng
hcfmusp.relation.referenceRanney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141eng
hcfmusp.relation.referenceRecalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387eng
hcfmusp.relation.referenceSarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337eng
hcfmusp.relation.referenceSchroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724eng
hcfmusp.relation.referenceSinghal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6eng
hcfmusp.relation.referenceSUEKI H, 1995, J INVEST DERMATOL, V105, P704, DOI 10.1111/1523-1747.ep12324502eng
hcfmusp.relation.referenceSundstrom JB, 2004, J IMMUNOL, V172, P4391, DOI 10.4049/jimmunol.172.7.4391eng
hcfmusp.relation.referenceTang X, 2020, CHEST, V158, P195, DOI 10.1016/j.chest.2020.03.032eng
hcfmusp.relation.referenceTeach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008eng
hcfmusp.relation.referenceTroupin A, 2016, J IMMUNOL, V197, P4382, DOI 10.4049/jimmunol.1600846eng
hcfmusp.relation.referenceTversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.xeng
hcfmusp.relation.referenceWada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069eng
hcfmusp.relation.referenceWaldman M, 2005, LUPUS, V14, P19, DOI 10.1191/0961203305lu2054oaeng
hcfmusp.relation.referenceXu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-Xeng
hcfmusp.relation.referenceZhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P302, DOI [10.3760/cma.j.issn.0253-2727.2020.0006, 10.3760/cma.j.issn.0253-2727.2020.008]eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication5ac06545-25cf-47e4-9c2a-97a8e835e0d9
relation.isAuthorOfPublication6188c80a-f4dc-42b3-9485-53e5190652a8
relation.isAuthorOfPublication0839c09a-a6cd-4be9-be33-b83fcd064a46
relation.isAuthorOfPublicatione9850765-f508-4f80-9a7d-41636a93a70f
relation.isAuthorOfPublication.latestForDiscovery5ac06545-25cf-47e4-9c2a-97a8e835e0d9
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_CRIADO_What_the_physicians_should_know_about_mast_cells_2020.PDF
Tamanho:
6.74 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/06
Carregar mais